Answers are grounded in this paper and cite their sources.
Analysis reveals drug response variability in patients with immune-mediated inflammatory diseases, suggesting targeted therapies need personalization.
Introduction: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a given drug. There is a big need to understand the factors that are associated with this heterogeneity.
No takes yet. Share an insight, caveat, or question.
Siegmund et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: